Stephen Carey Sells 3,312 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,312 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.00, for a total value of $264,960.00. Following the transaction, the chief financial officer directly owned 180,393 shares in the company, valued at approximately $14,431,440. This represents a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $81.85 on Thursday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market cap of $1.86 billion, a P/E ratio of 20.72 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 52 week low of $61.17 and a 52 week high of $99.50. The company has a 50-day moving average price of $79.51 and a 200 day moving average price of $79.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same period last year, the firm earned $1.70 EPS. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current year.

Analysts Set New Price Targets

ANIP has been the subject of several research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Divisadero Street Capital Management LP bought a new position in shares of ANI Pharmaceuticals in the third quarter worth about $21,454,000. Apis Capital Advisors LLC raised its stake in shares of ANI Pharmaceuticals by 28.1% during the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after buying an additional 36,000 shares during the last quarter. Oliver Luxxe Assets LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth approximately $1,823,000. Vanguard Group Inc. raised its stake in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares during the last quarter. Finally, Artemis Investment Management LLP bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth approximately $1,706,000. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.